fda glp-1 compounding enforcement news Medvi Warning Exposes Gaps What Patients Need to Know

This means insulin release occurs primarily when blood sugar is elevated, reducing the risk of hypoglycaemia compared to some other diabetes medications

EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome

Your gut microbiome is home to millions of bacteria and other microorganisms living in your digestive system

ANPA-0073 has completed its Phase 1 dosing study and the company is evaluating it for Phase 2 trials